CAJ | 학술논문

目的：观察前列腺液中卵磷脂腺体数量、前列腺压痛、病程和和 NIH －CPSI 的疼痛症状评分，排尿症状评分、生活质量评分、总评分及中医症状评分的相关性，观察ⅢB 型前列腺炎经复方土茯苓片干预后症状评分与客观指标变化，评价复方土茯苓片联合甲磺酸多沙唑嗪缓释片治疗ⅢB 型前列腺炎的临床疗效。方法：本研究是一个前瞻性、随机、双盲、对照的临床试验，将我院泌尿外科门诊120例ⅢB 型前列腺炎患者纳入研究，随机分为复方土茯苓片干预组及对照组，对照组给予甲磺酸多沙唑嗪缓释片联合复方土茯苓片安慰剂治疗，治疗组给予甲磺酸多沙唑嗪缓释片联合复方土茯苓片，分别对ⅢB 型前列腺炎患者入组前及入组后第2、4周进行随访。结果：干预28d 时治疗组中 NIH －CPSI 和中医症状评分较对照组显著降低，差异有统计学意义（P ＜0.01）。EPS 中不同卵磷脂小体水平的 NIH －CPSI 评分及中医症状评分之间无统计学差异（P ＞0.05）。不同前列腺压痛程度的 NIH －CPSI 评分及中医症状评分之间无统计学差异（P ＞0.05）。NIH －CPSI 评分方面，复方土茯苓片组14d 有效77.2％，对照组有效（6.9％），差异有统计学意义（P＜0.01）；复方土茯苓片组28d 后，显效者占绝大多数（84.2％），对照组有效（12.1％），差异有统计学意义（P ＜0.01）；中医症状评分方面，复方土茯苓片组14天有效（54.4％），对照组患者有效（8.6％），差异有统计学意义（P ＜0.001）；复方土茯苓片组28天后，显效者占到主要部分（68.4％），对照组有效（13.8％），差异有统计学意义（P ＜0.01）。结论：前列腺液中卵磷脂腺体数量、前列腺压痛、病程和 NIH －CPI 的疼痛症状评分，排尿症状评分、生活质量评分、总评分及中医症状评分均无相关性；复方土茯苓片治疗ⅢB 型前列腺炎在症状缓解方面明显优于应用甲磺酸多沙唑嗪缓释片联合安慰剂对照组。目的：觀察前列腺液中卵燐脂腺體數量、前列腺壓痛、病程和和 NIH －CPSI 的疼痛癥狀評分，排尿癥狀評分、生活質量評分、總評分及中醫癥狀評分的相關性，觀察ⅢB 型前列腺炎經複方土茯苓片榦預後癥狀評分與客觀指標變化，評價複方土茯苓片聯閤甲磺痠多沙唑嗪緩釋片治療ⅢB 型前列腺炎的臨床療效。方法：本研究是一箇前瞻性、隨機、雙盲、對照的臨床試驗，將我院泌尿外科門診120例ⅢB 型前列腺炎患者納入研究，隨機分為複方土茯苓片榦預組及對照組，對照組給予甲磺痠多沙唑嗪緩釋片聯閤複方土茯苓片安慰劑治療，治療組給予甲磺痠多沙唑嗪緩釋片聯閤複方土茯苓片，分彆對ⅢB 型前列腺炎患者入組前及入組後第2、4週進行隨訪。結果：榦預28d 時治療組中 NIH －CPSI 和中醫癥狀評分較對照組顯著降低，差異有統計學意義（P ＜0.01）。EPS 中不同卵燐脂小體水平的 NIH －CPSI 評分及中醫癥狀評分之間無統計學差異（P ＞0.05）。不同前列腺壓痛程度的 NIH －CPSI 評分及中醫癥狀評分之間無統計學差異（P ＞0.05）。NIH －CPSI 評分方麵，複方土茯苓片組14d 有效77.2％，對照組有效（6.9％），差異有統計學意義（P＜0.01）；複方土茯苓片組28d 後，顯效者佔絕大多數（84.2％），對照組有效（12.1％），差異有統計學意義（P ＜0.01）；中醫癥狀評分方麵，複方土茯苓片組14天有效（54.4％），對照組患者有效（8.6％），差異有統計學意義（P ＜0.001）；複方土茯苓片組28天後，顯效者佔到主要部分（68.4％），對照組有效（13.8％），差異有統計學意義（P ＜0.01）。結論：前列腺液中卵燐脂腺體數量、前列腺壓痛、病程和 NIH －CPI 的疼痛癥狀評分，排尿癥狀評分、生活質量評分、總評分及中醫癥狀評分均無相關性；複方土茯苓片治療ⅢB 型前列腺炎在癥狀緩解方麵明顯優于應用甲磺痠多沙唑嗪緩釋片聯閤安慰劑對照組。
목적：관찰전렬선액중란린지선체수량、전렬선압통、병정화화 NIH －CPSI 적동통증상평분，배뇨증상평분、생활질량평분、총평분급중의증상평분적상관성，관찰ⅢB 형전렬선염경복방토복령편간예후증상평분여객관지표변화，평개복방토복령편연합갑광산다사서진완석편치료ⅢB 형전렬선염적림상료효。방법：본연구시일개전첨성、수궤、쌍맹、대조적림상시험，장아원비뇨외과문진120례ⅢB 형전렬선염환자납입연구，수궤분위복방토복령편간예조급대조조，대조조급여갑광산다사서진완석편연합복방토복령편안위제치료，치료조급여갑광산다사서진완석편연합복방토복령편，분별대ⅢB 형전렬선염환자입조전급입조후제2、4주진행수방。결과：간예28d 시치료조중 NIH －CPSI 화중의증상평분교대조조현저강저，차이유통계학의의（P ＜0.01）。EPS 중불동란린지소체수평적 NIH －CPSI 평분급중의증상평분지간무통계학차이（P ＞0.05）。불동전렬선압통정도적 NIH －CPSI 평분급중의증상평분지간무통계학차이（P ＞0.05）。NIH －CPSI 평분방면，복방토복령편조14d 유효77.2％，대조조유효（6.9％），차이유통계학의의（P＜0.01）；복방토복령편조28d 후，현효자점절대다수（84.2％），대조조유효（12.1％），차이유통계학의의（P ＜0.01）；중의증상평분방면，복방토복령편조14천유효（54.4％），대조조환자유효（8.6％），차이유통계학의의（P ＜0.001）；복방토복령편조28천후，현효자점도주요부분（68.4％），대조조유효（13.8％），차이유통계학의의（P ＜0.01）。결론：전렬선액중란린지선체수량、전렬선압통、병정화 NIH －CPI 적동통증상평분，배뇨증상평분、생활질량평분、총평분급중의증상평분균무상관성；복방토복령편치료ⅢB 형전렬선염재증상완해방면명현우우응용갑광산다사서진완석편연합안위제대조조。
Objectives:To explore the curative effect of compound Tufuling tablets combined with doxazosin mesylate extended -release tablets in treatment of type IIIB prostatitis,through analyzing correlation of the number of lecithin glands in prostatic fluid,prostate tenderness,pain symptoms,course of disease,NIH -CPSI score,voi-ding symptom score,scores of life quality,total score and scores of TCM symptoms,and observation of the symp-toms score and objective index change in IIIB type of prostatitis after intervened by compound Tufuling tablets. Methods:This study was a prospective,randomized,double blind,controlled clinical trial.120 patients with type III B prostatitis in our hospital were randomly divided into compound Tufuling tablets intervention group and control group.The control group was given doxazosin mesylate extended -release tablets combined with compound Tufuling tablets placebo treatment,and the treatment group was given doxazosin mesylate extended -release tablets combined with compound Tufuling tablets.The patient with type III B prostatitis before and 2,4 weeks after treatment was fol-lowed up.Results:After intervention of 28 days,the NIH -CPSI and TCMsymptom score in treatment group was significantly lower than the control group,with statistically significant difference (P <0.01).Differences in EPS NIH -CPSI score and clinical symptoms score between different levels of lecithin corpuscle was not significant (P >0.05).Difference in NIH -CPSI score and clinical symptoms score between different prostate tenderness degrees was not statistically significant (P >0.05).In terms of NIH -CPSI score,the 14 -day effective rate of compound Tufuling tablets group and control group was 77.2% and 6.9%,with statistically significant difference (P <0.01);the 28 -day effective rate of compound Tufuling tablets group and control group was 84.2% and 12.1%, with statistically significant difference (P <0.01).In terms of TCM symptom score,the 14 -day effective rate of compound Tufuling tablets group and control group was 54.4% and 8.6% respectively,with statistically significant difference (P <0.001);the 28 -day effective rate of compound Tufuling tablets group and control group was 68. 4% and 13.8%,with statistically significant difference (P <0.01).Conclusion:The number of lecithin gland in prostatic fluid,prostate tenderness,course of disease,NIH -CPSI pain score,voiding symptom score,score of life quality,total score and scores of TCMsymptoms are not correlated.The effect of compound Tufuling tablets in trea-ting type III B prostatitis is significantly better than the doxazosin mesylate extended -release tablets plus placebo.